



Universiteit
Leiden

The Netherlands

Advancing AAV5-mediated gene therapy for brain and liver indications: preclinical assessment of biodistribution, efficacy and safety in animal models

Spronck, E.A.

Citation


Spronck, E. A. (2025, September 4). *Advancing AAV5-mediated gene therapy for brain and liver indications: preclinical assessment of biodistribution, efficacy and safety in animal models*. Retrieved from <https://hdl.handle.net/1887/4259688>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4259688>

Note: To cite this publication please use the final published version (if applicable).

A 3D rendering of several AAV5 virus particles. The particles are spherical with a complex, bumpy surface texture. They are colored in shades of orange, red, and blue, with a glowing effect. The background is a gradient of orange and blue, with some faint, wispy lines and small dots, suggesting a microscopic or cellular environment.

ADVANCING AAV5-MEDIATED GENE THERAPY FOR BRAIN AND LIVER INDICATIONS

**PRECLINICAL ASSESSMENT OF BIODISTRIBUTION,
EFFICACY, AND SAFETY IN ANIMAL MODELS**

ELISABETH ANNA SPRONCK